Generation of Trp53 Gene Knockout Mouse and Its Application in Carcinogenicity Assessment of Pharmaceuticals

doi:10.3969/j.issn.1674-5817.2013.06.002

Abstract

Abstract: Objective To establish Trp53 gene knockout mouse. Methods Using ET cloning, homologous recombination, microinjection technology, the Trp53 gene knockout mouse with the deletion of exons 2 to 11 was established. PCR, RT-PCR and Western blot were used to detect the expression of Trp53 in Trp53^+/+, Trp53^+/-and Trp53^-/-mice. The phenotype of the knockout mice was analyzed by spontaneous tumors observation and histopathological examination. The susceptibility of Trp53 heterozygote (+/-) and wild type (+/+) mice to N-methyl-N-nitrosourea (MNU) was investigated to assess the application of the knockout mouse in carcinogenicity assessment of pharmaceuticals. Results PCR, RT-PCR and Western blot confirmed the deletion of Trp53 gene in the knockout mouse. Trp53^-/-mice appear normal but are highly susceptible to genesis of a variety of tumors at a very early age-13 weeks of age and all have developed tumor and died by 36 weeks of age. These mice developed many deferent types of tumors, but the most frequently observed tumor is malignant lymphoma, occurring in more than 60% of the mice. Mortality from N-methyl-N-nitrosourea (MNU)-induced lymphomas was much greeter in Trp53^+/- group. After a single intraperitoneal injection of MNU at dose of 75mg/kg in twenty male and female Trp53^+/-and Trp53^+/+mice, eighteen male Trp53^+/-mice or female mice developed tumors, especially the malignant lymphoma of thymus, Trp53^+/- in mice 86%. Twenty Trp53^+/-mice and Trp53^+/+mice per sex receiving a single intraperitoneal injection of citrate buffer appeared normal and no tumor was found. Conclusion The Trp53 gene knockout mice have been established , which can be use in the function study of Trp53 gene and the carcinogenicity assessment of pharmaceuticals.

Key words: Trp53 gene, Gene knockout, Tumorigenesis, Drug carcinogenicity assessment

LIN Dan, ZHENG Jin-hua, ZHUANG Hua, SHI Ji-jing, LIN Yue-lin, WANG Zhu-gang, KUANG Ying. Generation of Trp53 Gene Knockout Mouse and Its Application in Carcinogenicity Assessment of Pharmaceuticals[J]. Laboratory Animal and Comparative Medicine, 2013, 33(6): 418-424.

References

[1] Hollstein M, Rice K, Greenblatt MS, et al.Database of p53 gene somatic mutations in human tumors and cell lines[J]. Nucleic Acid Res, 1994, 22(17):3551-3555.
[2] Donehower LA, Lozano G.20 years studying p53 functions in genetically engineered mice[J]. Nat Rev Cancer, 2009, 9(11):831-841.
[3] 宋征, 徐景宏, 王庆利, 等. 转基因小鼠在药物致癌性评价中的应用[J]. 中国药理学与毒理学杂志, 2010, 24(6):557-561.
[4] 杨建岭, 顾淑萍, 陈臣, 等. 用RED/ET重组酶构建基因打靶载体[J].生物工程学报, 2006, 22(6):919-924.
[5] 孙莲花, 陈燕, 麻孙恺, 等. TAFA2基因剔除小鼠模型的建立[J]. 实验动物与比较医学, 2010, 30(5):322-328.
[6] Donehower LA,Harvey M, Slagle BL, et al.Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours[J]. Nature, 1992, 356(6366):215-221.
[7] Jacks T, Remington L, Williams BO, et al.Tumor spectrum analysis in p53-mutant mice[J]. Curr Biol, 1994, 4(1):1-7.
[8] Tsukada T, Tomooka Y, Takai S, et al.Enhanced proliferative potential in culture of cells from p53-deficient mice[J].Oncogene, 1993, 8(12):3313-3322.
[9] Kuperwasser C, Hurlbut GD, Kittrell FS, et al.Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome[J]. Am J Pathol, 2000, 157(6):2151-2159.
[10] Harvey M, McArthur MJ, Montgomery CA Jr, et al.Genetic background alters spectrum of tumors that develop in p53-deficient mice[J]. FASEB J, 1993, 7(10):938-943.
[11] Morton D, Bailey KL, Stout CL,et al.N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies[J].Toxicol Pathol, 2008, 36(7):926-931.
[12] Floyd E, Mann P, Long G, et al.The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists[J]. Toxicol Pathol, 2002, 30(1):147-156.
[13] Hoivik DJ, Allen JS, Wall HG, et al.Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse[J]. Intl J Toxicol,2005, 24(5):349-356.